

*Time:* October 11, 7:30 p.m.—recess; October 12, 8 a.m.—recess; October 13, 8 a.m.—adjournment.

*Place:* Hampshire Hotel, 1310 New Hampshire Avenue, N.W., Washington, DC 20036.

*Contact Person:* Dr. Paul Sheehy, Scientific Review Administrator, National Institutes of Health, Federal Building, Room 9C-10, Bethesda, MD 20892, (301) 496-9223.

*Name of Committee:* Neurological Disorders Program Project Review A Committee.

*Date:* October 25-27, 1995.

*Time:* October 25, 7:30 p.m.—recess; October 26, 8:30 a.m.—recess; October 27, 8:30 a.m.—adjournment.

*Place:* Bethesda Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Dr. Katherine Woodbury, Scientific Review Administrator, National Institutes of Health, Federal Building, Room 9C-14, Bethesda, MD 20892, (301) 496-9223.

*Name of Committee:* Training Grant and Career Development Review Committee.

*Date:* November 8-10, 1995.

*Time:* November 8, 9 a.m.—recess; November 9, 8:30 a.m.—recess; November 10, 8:30 a.m.—adjournment.

*Place:* Hyatt Islandia, San Diego's Mission Bay, 1441 Quivira Road, San Diego, CA 92109-7898.

*Contact Person:* Dr. Alfred Gordon, Scientific Review Administrator, National Institutes of Health, Federal Building, Room 9C-14, Bethesda, MD 20892, (301) 496-9223.

(Catalog of Federal Domestic Assistance Program No. 93.853, Clinical Research Related to Neurological Disorders; No. 93.854, Biological Basis Research in the Neurosciences)

Dated: July 24, 1995.

**Susan K. Feldman,**

*Committee Management Officer, National Institutes of Health.*

[FR Doc. 95-18531 Filed 7-27-95; 8:45 am]

BILLING CODE 4140-01-M

### Division of Research Grants; Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

*Purpose/Agenda:* To review individual grant applications.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* August 8, 1995.

*Time:* 4:00 p.m.

*Place:* NIH, Rockledge II, Room 4208, Telephone Conference.

*Contact Person:* Dr. Anita Weinblatt, Scientific Review Administrator, 6701 Rockledge Drive, Room 4208, Bethesda, MD 20892, (301) 435-1224.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* August 10, 1995.

*Time:* 2:30 p.m.

*Place:* NIH, Rockledge II, Room 4150, Telephone Conference.

*Contact Person:* Dr. Marcia Litwack, Scientific Review Administrator, 6701 Rockledge Drive, Room 4150, Bethesda, MD 20892, (301) 435-1719.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* August 14, 1995.

*Time:* 1:00 p.m.

*Place:* NIH, Rockledge II, Room 4200, Telephone Conference.

*Contact Person:* Dr. Gilbert Meier, Scientific Review Administrator, 6701 Rockledge Drive, Room 4200, Bethesda, MD 20892, (301) 435-1219.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* August 15, 1995.

*Time:* 10:00 a.m.

*Place:* NIH, Rockledge II, Room 4150, Telephone Conference.

*Contact Person:* Dr. Marcia Litwack, Scientific Review Administrator, 6701 Rockledge Drive, Room 4150, Bethesda, MD 20892, (301) 435-1719.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets of commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 24, 1995.

**Susan K. Feldman,**

*Committee Management Officer, NIH.*

[FR Doc. 95-18537 Filed 7-27-95; 8:45 am]

BILLING CODE 4140-01-M

### Prospective Grant of Exclusive License: Mouse Monoclonal Antibodies Specific for Normal Primate Tissue, Malignant Human Cultured Cell Lines and Human Tumors

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health

and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in U.S. Patent 5,242,813, U.S. Patent Applications 08/051,133 and 08/363,203 and corresponding foreign patent applications entitled "Mouse Monoclonal Antibodies Specific For Normal Primate Tissue, Malignant Human Cultured Cell Lines and Human Tumors" to Pharmacia, S.P.A. of Milano, Italy. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The present invention includes three murine monoclonal antibodies (MAb), B1, B3 and B5. These antibodies react strongly with the Lewis Y blood group antigen on many human solid tumors but weakly with normal human tissues. MAb B3 reacts strongly with 10% of transitional cell carcinomas of the bladder, 75% of adenocarcinomas of the colon, 70% of adenocarcinomas of the lung, 65% with adenocarcinomas of the prostate, 40% of squamous cell carcinomas of the lung and 25% of large cell carcinomas. MAb B3 reacts heterogeneously with 70% of breast carcinomas. Several important characteristics of this antibody make it an ideal candidate for further development: (1) Its strong and uniform reactivity with many human solid carcinomas; (2) its limited reactivity with normal tissues; (3) its expression on both human and monkey tissues will allow for predictive preclinical toxicology studies in monkeys. Additionally, these antibodies, when incorporated as the targeting element of an immunotoxin, have been shown to allow efficient entry of toxin agents into cells. These antibodies should be useful in the diagnosis and treatment of some forms of cancer.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Raphe Kantor, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804. Telephone: (301)

496-7735 ext. 247; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications. Applications for a license in the any field of use filed in response to this notice will be treated as objections to the grant to the contemplated licenses. Only written comments and/or applications for a license which are received by NIH on or before September 26, 1995 will be considered. Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act, 5 U.S.C. 552.

Dated: July 17, 1995.

**Barbara M. McGarey,**

*Deputy Director, Office of Technology Transfer.*

[FR Doc. 95-18528 Filed 7-27-95; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

### Office of the Assistant Secretary for Community Planning and Development

[Docket No. FR-3778-N-47]

#### Federal Property Suitable as Facilities to Assist the Homeless

**AGENCY:** Office of the Assistant Secretary for Community Planning and Development, HUD.

**ACTION:** Notice.

**SUMMARY:** This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.

**ADDRESSES:** For further information, contact David Pollack, room 7256, Department of Housing and Urban Development, 451 Seventh Street SW, Washington, DC 20410; telephone (202) 708-1234; TDD number for the hearing- and speech-impaired (202) 708-2565 (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1-800-927-7588.

**SUPPLEMENTARY INFORMATION:** In accordance with 56 FR 23789 (May 24, 1991) and section 501 of the Stewart B. McKinney Homeless Assistance Act (42 U.S.C. 11411), as amended, HUD is publishing this Notice to identify Federal buildings and other real property that HUD has reviewed for suitability for use to assist the homeless. The properties were reviewed using information provided to HUD by Federal landholding agencies regarding

unutilized and underutilized buildings and real property controlled by such agencies or by GSA regarding its inventory of excess or surplus Federal property. This Notice is also published in order to comply with the December 12, 1988 Court Order in *National Coalition for the Homeless v. Veterans Administration*, No. 88-2503-OG (D.D.C.).

Properties reviewed are listed in this Notice according to the following categories: Suitable/available, suitable/unavailable, suitable/to be excess, and unsuitable. The properties listed in the three suitable categories have been reviewed by the landholding agencies, and each agency has transmitted to HUD: (1) Its intention to make the property available for use to assist the homeless, (2) its intention to declare the property excess to the agency's needs, or (3) a statement of the reasons that the property cannot be declared excess or made available for use as facilities to assist the homeless.

Properties listed as suitable/available will be available exclusively for homeless use for a period of 60 days from the date of this Notice. Homeless assistance providers interested in any such property should send a written expression of interest to HHS, addressed to Judy Breitman, Division of Health Facilities Planning, U.S. Public Health Service, HHS, room 17A-10, 5600 Fishers Lane, Rockville, MD 20857; (301) 443-2265. (This is not a toll-free number.) HHS will mail to the interested provider an application packet, which will include instructions for completing the application. In order to maximize the opportunity to utilize a suitable property, providers should submit their written expressions of interest as soon as possible. For complete details concerning the processing of applications, the reader is encouraged to refer to the interim rule governing this program, 56 FR 23789 (May 24, 1991).

For properties listed as suitable/to be excess, that property may, if subsequently accepted as excess by GSA, be made available for use by the homeless in accordance with applicable law, subject to screening for other Federal use. At the appropriate time, HUD will publish the property in a Notice showing it as either suitable/available or suitable/unavailable.

For properties listed as suitable/unavailable, the landholding agency has decided that the property cannot be declared excess or made available for use to assist the homeless, and the property will not be available.

Properties listed as unsuitable will not be made available for any other

purpose for 20 days from the date of this Notice. Homeless assistance providers interested in a review by HUD of the determination of unsuitability should call the toll free information line at 1-800-927-7588 for detailed instructions or write a letter to David Pollack at the address listed at the beginning of this Notice. Included in the request for review should be the property address (including zip code), the date of publication in the **Federal Register**, the landholding agency, and the property number.

For more information regarding particular properties identified in this Notice (*i.e.*, acreage, floor plan, existing sanitary facilities, exact street address), providers should contact the appropriate landholding agencies at the following addresses: U.S. Navy: John J. Kane, Deputy Division Director, Dept. of Navy, Real Estate Operations, Naval Facilities Engineering Command, 200 Stovall Street, Alexandria, VA 22332-2300; (703) 325-0474; (This is not a toll-free number).

Dated: July 21, 1995.

**Jacque M. Lawing,**

*Deputy Assistant Secretary for Economic Development.*

#### Title V, Federal Surplus Property Program Federal Register Report for 07/28/95

*Unsuitable Properties—Building (by State)*

Washington

Bldg. 101

Pacific Northwest Fleet Recreation and

Education Support Center

Pacific Beach, WA

Landholding Agency: Navy

Property Number: 779530001

Status: Excess

Reason: Extensive deterioration.

Bldg. 129

Pacific Northwest Fleet Recreation and

Education Support Center

Pacific Beach, WA

Landholding Agency: Navy

Property Number: 779530002

Status: Excess

Reason: Extensive deterioration.

Bldg. 131

Pacific Northwest Fleet Recreation and

Education Support Center

Pacific Beach, WA

Landholding Agency: Navy

Property Number: 779530003

Status: Excess

Reason: Extensive deterioration.

Bldg. 136

Pacific Northwest Fleet Recreation and

Education Support Center

Pacific Beach, WA

Landholding Agency: Navy

Property Number: 779530004

Status: Excess

Reason: Extensive deterioration.

[FR Doc. 95-18412 Filed 7-27-95; 8:45 am]

BILLING CODE 4210-29-M